Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer

Role of the pro-survival molecule Bfl-1 in melanoma

(2015) C.K. Hind et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Kojak: Efficient Analysis of Chemically Cross-Linked Protein Complexes

(2015) Michael R. Hoopmann et al.   JOURNAL OF PROTEOME RESEARCH

Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer

(2015) Haichao Zhang et al.   Molecular Cancer

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

The molecular architecture of the Dam1 kinetochore complex is defined by cross-linking based structural modelling

(2015) Alex Zelter et al.   Nature Communications

An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo

(2015) Brandon J. Aubrey et al.   Cell Reports

Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in Cells

(2014) Glenna Wink Foight et al.   ACS Chemical Biology

A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells

(2014) Erik Procko et al.   CELL

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

(2014) G. L. Kelly et al.   GENES & DEVELOPMENT

Peptide Ligands for Pro-survival Protein Bfl-1 from Computationally Guided Library Screening

(2013) Sanjib Dutta et al.   ACS Chemical Biology

Computational Design of a Protein-Based Enzyme Inhibitor

(2013) Erik Procko et al.   JOURNAL OF MOLECULAR BIOLOGY

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

In Silico and in Vitro Elucidation of BH3 Binding Specificity toward Bcl-2

(2012) Nir London et al.   BIOCHEMISTRY

Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter

(2012) Khatri Latha et al.   INTERNATIONAL JOURNAL OF CANCER

Predictive Bcl-2 Family Binding Models Rooted in Experiment or Structure

(2012) Joe DeBartolo et al.   JOURNAL OF MOLECULAR BIOLOGY

Overview of theCCP4 suite and current developments

(2011) Martyn D. Winn et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Enrich: software for analysis of protein function by enrichment and depletion of variants

(2011) Douglas M. Fowler et al.   BIOINFORMATICS

The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy

(2011) P N Kelly et al.   CELL DEATH AND DIFFERENTIATION

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization

(2011) Haiming Dai et al.   JOURNAL OF CELL BIOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria

(2011) Fabien Llambi et al.   MOLECULAR CELL

RosettaScripts: A Scripting Language Interface to the Rosetta Macromolecular Modeling Suite

(2011) Sarel J. Fleishman et al.   PLoS One

Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin

(2011) S. J. Fleishman et al.   SCIENCE

BH3-only proteins: Orchestrators of apoptosis

(2010) Aisha Shamas-Din et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX

(2010) Bonsu Ku et al.   CELL RESEARCH

Determinants of BH3 Binding Specificity for Mcl-1 versus Bcl-xL

(2010) Sanjib Dutta et al.   JOURNAL OF MOLECULAR BIOLOGY

Computational Design of Epitope-Scaffolds Allows Induction of Antibodies Specific for a Poorly Immunogenic HIV Vaccine Epitope

(2010) Bruno E. Correia et al.   STRUCTURE

Phosphorylation of Puma modulates its apoptotic function by regulating protein stability

(2010) M Fricker et al.   Cell Death & Disease

A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy

(2010) W J Placzek et al.   Cell Death & Disease

Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis

(2009) Hyungjin Kim et al.   MOLECULAR CELL

The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor

(2009) Y.-P. Rong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation

(2008) Erinna F. Lee et al.   JOURNAL OF CELL BIOLOGY